<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03655925</url>
  </required_header>
  <id_info>
    <org_study_id>170687</org_study_id>
    <nct_id>NCT03655925</nct_id>
  </id_info>
  <brief_title>Human Leucocyte Antigen G and Chronic Heart Failure</brief_title>
  <official_title>Plasma Levels of Human Leucocyte Antigen G in Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piera Boschetto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Human leukocyte antigen G (HLA-G) is a non-classical, major histocompatibility complex
      class I (MHC-I) protein that modulates the immune response, inhibiting it in most cases.
      Physiologically expressed in the cells of some tissues, it increases in inflammatory
      reactions. Inflammation appears to play an important role in the development of chronic heart
      failure. This study aims to evaluate the levels of soluble HLA-G in patients with heart
      failure and to investigate the relationships between HLA-G and other clinical-functional
      parameters of the disease. Investigators hypothesize that the plasma levels of HLA-G could
      correlate with the clinical status of heart failure and could provide indications on
      patient's prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Actual">March 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To measure plasma levels of soluble Human Leucocyte Antigen G (HLA-G) in patients with chronic heart failure (CHF)</measure>
    <time_frame>Collection of whole blood at baseline, at 6 and 12 months from baseline</time_frame>
    <description>To measure the plasmatic levels of HLA-G in patients with stable chronic heart failure at baseline. To assess possible changes in HLA-G levels, due to CHF exacerbations, at 6 and 12 months from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To measure the polymorphisms of Human Leucocyte Antigen G (HLA-G) gene</measure>
    <time_frame>Collection of whole blood at baseline</time_frame>
    <description>To analyze the polymorphisms (Insertion/Deletion 14 pb and 3142 C&gt;G) of the HLA-G gene in patients with chronic heart failure (CHF) at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate the plasma levels of HLA-G with clinical-functional parameters of the chronic heart failure (CHF) in patients with CHF</measure>
    <time_frame>At baseline and after 12 months</time_frame>
    <description>To correlate plasma levels of HLA-G with Brain Natriuretic Peptide (BNP) and left ventricle ejection fraction at baseline and at 12 months from baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Patients with Chronic Heart Failure (CHF)</arm_group_label>
    <description>Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction &lt;40</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>plasmatic HLA-G</intervention_name>
    <description>plasmatic HLA-G by blood sample</description>
    <arm_group_label>Patients with Chronic Heart Failure (CHF)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 subjects with chronic stable heart failure with ejection fraction &lt;40, diagnosed
        according to the European Society of Cardiology Guidelines
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recent diagnosis of chronic heart failure as defined by the guidelines
             of the European Society of Cardiology (ESC) and with cardiac ejection fraction &lt;40.

          -  Clinical stability in the previous month prior to recruitment.

          -  Absence of coexisting autoimmune diseases.

        Exclusion Criteria:

          -  Subjects with over one year chronic heart failure diagnosis and in clinical stability
             for less than 1 month.

          -  Presence of autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Sciences/ Medicine of Public Health</name>
      <address>
        <city>Ferrara</city>
        <zip>44121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Alegre E, Rizzo R, Bortolotti D, Fernandez-Landázuri S, Fainardi E, González A. Some basic aspects of HLA-G biology. J Immunol Res. 2014;2014:657625. doi: 10.1155/2014/657625. Epub 2014 Apr 9. Review.</citation>
    <PMID>24818168</PMID>
  </reference>
  <reference>
    <citation>Almasood A, Sheshgiri R, Joseph JM, Rao V, Kamali M, Tumiati L, Ross HJ, Delgado DH. Human leukocyte antigen-G is upregulated in heart failure patients: a potential novel biomarker. Hum Immunol. 2011 Nov;72(11):1064-7. doi: 10.1016/j.humimm.2011.08.016. Epub 2011 Sep 1.</citation>
    <PMID>21925559</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Piera Boschetto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

